Incorporation of membrane-bound, mammalian-derived immunomodulatory proteins into influenza whole virus vaccines boosts immunogenicity and protection against lethal challenge

Virology Journal

Volumn 6, Issue , 2009, Pages

  Herbert, Andrew S ^a   Heffron, Lynn ^a   Sundick, Roy ^b   Roberts, Paul C ^a  

^a CENTER FOR MOLECULAR MEDICINE AND INFECTIOUS DISEASES   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 4; VIRUS ANTIBODY; VIRUS FUSION PROTEIN; VIRUS HEMAGGLUTININ; CYTOKINE; IMMUNOLOGIC FACTOR; INACTIVATED VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CELL STRAIN; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOMODULATION; INFLUENZA; LOW DRUG DOSE; MOUSE; NONHUMAN; SINGLE DRUG DOSE; TH1 CELL; TH2 CELL; TREATMENT OUTCOME; VIRION; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; BLOOD; CELL LINE; DOG; GENETICS; IMMUNOLOGY; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; LUNG; ORTHOMYXOVIRUS INFECTION; VIROLOGY;

AVES; MAMMALIA; ORTHOMYXOVIRIDAE;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CELL LINE; CYTOKINES; DOGS; FEMALE; IMMUNOLOGIC FACTORS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; LUNG; MICE; ORTHOMYXOVIRIDAE INFECTIONS; TH1 CELLS; VACCINES, INACTIVATED; VIRAL LOAD;

EID: 65549139794     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-6-42     Document Type: Article

References (70)

1. Update: influenza activity - United States and worldwide, 2005-06 season, and composition of the 2006-07 influenza vaccine. MMWR Morb Mortal Wkly Rep 2006 55 648 653 16775576
2. Pandemic threat posed by avian influenza A viruses. T Horimoto Y Kawaoka, Clin Microbiol Rev 2001 14 129 149 11148006 10.1128/CMR.14.1.129-149.2001
3. Re-emergence of fatal human influenza A subtype H5N1 disease. JS Peiris WC Yu CW Leung CY Cheung WF Ng JM Nicholls TK Ng KH Chan ST Lai WL Lim KY Yuen Y Guan, Lancet 2004 363 617 619 10.1016/S0140-6736(04)15595-5 14987888
4. Epidemiology of WHO-confirmed human cases of avian influenza A(H5N1) infection. Wkly Epidemiol Rec 2006 81 249 257 16812929
5. Probable person-to-person transmission of avian influenza A (H5N1). K Ungchusak P Auewarakul SF Dowell R Kitphati W Auwanit P Puthavathana M Uiprasertkul K Boonnak C Pittayawonganon NJ Cox SR Zaki P Thawatsupha M Chittaganpitch R Khontong JM Simmerman S Chunsutthiwat, N Engl J Med 2005 352 333 340 10.1056/NEJMoa044021 15668219
6. Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine. Y Kuroda DC Nacionales J Akaogi WH Reeves M Satoh, Biomed Pharmacother 2004 58 325 337 10.1016/j.biopha.2004.04.009 15194169
7. Heterotypic protection against influenza by immunostimulating complexes is associated with the induction of cross-reactive cytotoxic T lymphocytes. S Sambhara S Woods R Arpino A Kurichh A Tamane B Underdown M Klein K Lovgren Bengtsson B Morein D Burt, J Infect Dis 1998 177 1266 1274 9593011
8. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. S Sambhara A Kurichh R Miranda T Tumpey T Rowe M Renshaw R Arpino A Tamane A Kandil O James B Underdown M Klein J Katz D Burt, Cell Immunol 2001 211 143 153 10.1006/cimm.2001.1835 11591118
9. Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. JP Valensi JR Carlson GA Van Nest, J Immunol 1994 153 4029 4039 7930610
10. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. I Leroux-Roels A Borkowski T Vanwolleghem M Drame F Clement E Hons JM Devaster G Leroux-Roels, Lancet 2007 370 580 589 10.1016/S0140-6736(07)61297-5 17707753
11. Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus. SM Kang RW Compans, J Virol 2003 77 3615 3623 12610137 10.1128/JVI.77.6.3615-3623.2003
12. Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. E Okada S Sasaki N Ishii I Aoki T Yasuda K Nishioka J Fukushima J Miyazaki B Wahren K Okuda, J Immunol 1997 159 3638 3647 9317164
13. IL-6 induces long-term protective immunity against a lethal challenge of influenza virus. SW Lee JW Youn BL Seong YC Sung, Vaccine 1999 17 490 496 10.1016/S0264-410X(98)00223-0 10073728
14. A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. II. Induction of TH1 and TH2 responses in mice. I Babai S Samira Y Barenholz Z Zakay-Rones E Kedar, Vaccine 1999 17 1239 1250 10.1016/S0264-410X(98)00347-8 10195637
15. The potential for recruiting immune responses toward type 1 or type 2 T cell help. B Golding M Zaitseva H Golding, Am J Trop Med Hyg 1994 50 33 40 8172330
16. Improved immunogenicity of a self tumor antigen by covalent linkage to CD40 ligand. HI Huang PY Wu CY Teo MN Chen YC Chen D Silin MH Tao, Int J Cancer 2004 108 696 703 10.1002/ijc.11612 14696096
17. Enhanced mucosal and systemic immunogenicity of human papillomavirus-like particles encapsidating interleukin-2 gene adjuvant. YK Oh T Sohn JS Park MJ Kang HG Choi JA Kim WK Kim JJ Ko CK Kim, Virology 2004 328 266 273 10.1016/j.virol.2004.06.047 15464846
18. Anchoring cytokines to tumor cells for the preparation of anticancer vaccines without gene transfection in mice. P Nizard DA Gross A Babon A Chenal B Beaumelle K Kosmatopoulos D Gillet, J Immunother 2003 26 63 71 10.1097/00002371-200301000-00007 12514430
19. A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and efficacy studies in mice. I Babai S Samira Y Barenholz Z Zakay-Rones E Kedar, Vaccine 1999 17 1223 1238 10.1016/S0264-410X(98)00346-6 10195636
20. IL-2 linked to a peptide from influenza hemagglutinin enhances T cell activation by affecting the antigen-presentation function of bone marrow-derived dendritic cells. L Faulkner G Buchan E Lockhart L Slobbe M Wilson M Baird, Int Immunol 2001 13 713 721 10.1093/intimm/13.6.713 11369698
21. Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine. S Yei RM Bartholomew P Pezzoli A Gutierrez E Gouveia D Bassett W Soo Hoo DJ Carlo, Gene Ther 2002 9 1302 1311 10.1038/sj.gt.3301803 12224013
22. A novel method to incorporate bioactive cytokines as adjuvants on the surface of virus particles. Y Yang D Leggat A Herbert PC Roberts RS Sundick, J Interferon Cytokine Res 2009 29 9 22 10.1089/jir.2008.0017 19014337
23. Counts of influenza virus particles. HB Donald A Isaacs, J Gen Microbiol 1954 10 457 464 13174769
24. Normal neutrophil differentiation and secondary granule gene expression in the EML and MPRO cell lines. ND Lawson DS Krause N Berliner, Exp Hematol 1998 26 1178 1185 9808058
25. Derivation of a T cell line that is highly responsive to IL-4 and IL-2 (CT.4R) and of an IL-2 hyporesponsive mutant of that line (CT.4S). J Hu-Li J Ohara C Watson W Tsang WE Paul, J Immunol 1989 142 800 807 2783601
26. RG Webster N Cox K Stohr, WHO Manual on Animal Influenza Diagnosis and Surveillance World Health Organization, Department of Communicable Disease Surveillance and Response; WHO/CDS/CDR/2002.5 Rev. 2002 1
27. A Simple Method of Estimating Fifty Percent End Points. LJ Reed H Muench, Am J Hyg 1938 27 493 497
28. Filamentous influenza A virus infection predisposes mice to fatal septicemia following superinfection with Streptococcus pneumoniae serotype 3. JL Speshock N Doyon-Reale R Rabah MN Neely PC Roberts, Infect Immun 2007 75 3102 3111 17403870 10.1128/IAI.01943-06
29. Host cell dependence of viral morphology. PC Roberts RW Compans, Proc Natl Acad Sci USA 1998 95 5746 5751 9576955 10.1073/pnas.95.10.5746
30. The M1 and M2 proteins of influenza A virus are important determinants in filamentous particle formation. PC Roberts RA Lamb RW Compans, Virology 1998 240 127 137 10.1006/viro.1997.8916 9448697
31. A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. SA Ahmed RM Gogal Jr JE Walsh, J Immunol Methods 1994 170 211 224 10.1016/0022-1759(94)90396-4 8157999
32. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. RJ Cox KA Brokstad P Ogra, Scand J Immunol 2004 59 1 15 10.1111/j.0300-9475.2004.01382. x 14723616
33. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. WE Beyer AM Palache JC de Jong AD Osterhaus, Vaccine 2002 20 1340 1353 10.1016/S0264-410X(01)00471-6 11818152
34. Recognition of single-stranded RNA viruses by Toll-like receptor 7. JM Lund L Alexopoulou A Sato M Karow NC Adams NW Gale A Iwasaki RA Flavell, Proc Natl Acad Sci USA 2004 101 5598 5603 15034168 10.1073/pnas.0400937101
35. The systemic and mucosal immune response of humans to influenza A virus. BR Murphy ML Clements, Curr Top Microbiol Immunol 1989 146 107 116 2659262
36. Determinants of immunity to influenza infection in man. CW Potter JS Oxford, Br Med Bull 1979 35 69 75 367490
37. Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. TG Boyce HH Hsu EC Sannella SD Coleman-Dockery E Baylis Y Zhu G Barchfeld A DiFrancesco M Paranandi B Culley KM Neuzil PF Wright, Vaccine 2000 19 217 226 10.1016/S0264-410X(00)00171-7 10930676
38. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. F Heil H Hemmi H Hochrein F Ampenberger C Kirschning S Akira G Lipford H Wagner S Bauer, Science 2004 303 1526 1529 10.1126/science.1093620 14976262
39. Parenteral influenza vaccination induces a rapid systemic and local immune response. KA Brokstad RJ Cox J Olofsson R Jonsson LR Haaheim, J Infect Dis 1995 171 198 203 7798664
40. An early humoral immune response in peripheral blood following parenteral inactivated influenza vaccination. RJ Cox KA Brokstad MA Zuckerman JM Wood LR Haaheim JS Oxford, Vaccine 1994 12 993 999 10.1016/0264-410X(94)90334-4 7975853
41. The effect of age and natural priming on the IgG and IgA subclass responses after parenteral influenza vaccination. AS El-Madhun RJ Cox LR Haaheim, J Infect Dis 1999 180 1356 1360 10.1086/315003 10479172
42. Systemic and mucosal immune responses in young children and adults after parenteral influenza vaccination. AS el-Madhun RJ Cox A Soreide J Olofsson LR Haaheim, J Infect Dis 1998 178 933 939 10.1086/515656 9806018
43. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. CM Snapper WE Paul, Science 1987 236 944 947 10.1126/science.3107127 3107127
44. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. BP Arulanandam M O'Toole DW Metzger, J Infect Dis 1999 180 940 949 10.1086/314996 10479116
45. Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice. AO Hovden RJ Cox LR Haaheim, Scand J Immunol 2005 62 36 44 10.1111/j.1365-3083.2005.01633. x 16092921
46. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. VC Huber JM Lynch DJ Bucher J Le DW Metzger, J Immunol 2001 166 7381 7388 11390489
47. Th2 responses to inactivated influenza virus can Be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection. TM Moran H Park A Fernandez-Sesma JL Schulman, J Infect Dis 1999 180 579 585 10.1086/314952 10438342
48. Role of the B-cell response in recovery of mice from primary influenza virus infection. W Gerhard K Mozdzanowska M Furchner G Washko K Maiese, Immunol Rev 1997 159 95 103 10.1111/j.1600-065X.1997.tb01009.x 9416505
49. A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro. K Mozdzanowska M Furchner G Washko J Mozdzanowski W Gerhard, J Virol 1997 71 4347 4355 9151823
50. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. VC Huber RM McKeon MN Brackin LA Miller R Keating SA Brown N Makarova DR Perez GH Macdonald JA McCullers, Clin Vaccine Immunol 2006 13 981 990 16960108 10.1128/CVI.00156-06
51. Functional diversity of helper T lymphocytes. AK Abbas KM Murphy A Sher, Nature 1996 383 787 793 10.1038/383787a0 8893001
52. IL-4 signaling, gene transcription regulation, and the control of effector T cells. M Boothby AL Mora MA Aronica J Youn JR Sheller S Goenka L Stephenson, Immunol Res 2001 23 179 191 10.1385/IR:23:2-3:179 11444383
53. The murine IgG1/IgE class switch program. G Siebenkotten C Esser M Wabl A Radbruch, Eur J Immunol 1992 22 1827 1834 10.1002/eji.1830220723 1623926
54. IL-4 is a mediator of IL-12p70 induction by human Th2 cells: reversal of polarized Th2 phenotype by dendritic cells. P Kalinski HH Smits JH Schuitemaker PL Vieira M van Eijk EC de Jong EA Wierenga ML Kapsenberg, J Immunol 2000 165 1877 1881 10925267
55. Plasmids encoding membrane-bound IL-4 or IL-12 strongly costimulate DNA vaccination against carcinoembryonic antigen (CEA). R Chakrabarti Y Chang K Song GJ Prud'homme, Vaccine 2004 22 1199 1205 10.1016/j.vaccine.2003.09.023 15003648
56. Interleukin (IL)-4 is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells. H Hochrein M O'Keeffe T Luft S Vandenabeele RJ Grumont E Maraskovsky K Shortman, J Exp Med 2000 192 823 833 10993913 10.1084/jem.192.6.823
57. Interleukin (IL)-4 inhibits IL-10 to promote IL-12 production by dendritic cells. Y Yao W Li MH Kaplan CH Chang, J Exp Med 2005 201 1899 1903 15967820 10.1084/jem.20050324
58. Production of IL-12 by human monocyte-derived dendritic cells is optimal when the stimulus is given at the onset of maturation, and is further enhanced by IL-4. S Ebner G Ratzinger B Krosbacher M Schmuth A Weiss D Reider RA Kroczek M Herold C Heufler P Fritsch N Romani, J Immunol 2001 166 633 641 11123347
59. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. G Parmiani C Castelli L Pilla M Santinami MP Colombo L Rivoltini, Ann Oncol 2007 18 226 232 10.1093/annonc/mdl158 17116643
60. Increased presence of CD34+ cells in the peripheral blood of head and neck cancer patients and their differentiation into dendritic cells. T Garrity R Pandit MA Wright J Benefield S Keni MR Young, Int J Cancer 1997 73 663 669 10.1002/(SICI)1097-0215(19971127)73:5<663::AID-IJC9>3.0.CO;2-V 9398043
61. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. N Hehme H Engelmann W Kuenzel E Neumeier R Saenger, Virus Res 2004 103 163 171 10.1016/j.virusres.2004.02.029 15163505
62. Roles of anti-hemagglutinin IgA and IgG antibodies in different sites of the respiratory tract of vaccinated mice in preventing lethal influenza pneumonia. R Ito YA Ozaki T Yoshikawa H Hasegawa Y Sato Y Suzuki R Inoue T Morishima N Kondo T Sata T Kurata S Tamura, Vaccine 2003 21 2362 2371 10.1016/S0264-410X(03)00078-1 12744867
63. Induction of innate immunity by nasal influenza vaccine administered in combination with an adjuvant (cholera toxin). K Matsuo T Yoshikawa H Asanuma T Iwasaki Y Hagiwara Z Chen SE Kadowaki H Tsujimoto T Kurata SI Tamura, Vaccine 2000 18 2713 2722 10.1016/S0264-410X(00)00055-4 10781859
64. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. M Mutsch W Zhou P Rhodes M Bopp RT Chen T Linder C Spyr R Steffen, N Engl J Med 2004 350 896 903 10.1056/NEJMoa030595 14985487
65. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. S Squarcione S Sgricia LR Biasio E Perinetti, Vaccine 2003 21 1268 1274 10.1016/S0264-410X(02)00401-2 12559808
66. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. S Tamura Y Ito H Asanuma Y Hirabayashi Y Suzuki T Nagamine C Aizawa T Kurata, J Immunol 1992 149 981 988 1634780
67. Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit. S Tamura Y Samegai H Kurata T Nagamine C Aizawa T Kurata, Vaccine 1988 6 409 413 10.1016/0264-410X(88)90140-5 2848377
68. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine. S Tamura A Yamanaka M Shimohara T Tomita K Komase Y Tsuda Y Suzuki T Nagamine K Kawahara H Danbara, Vaccine 1994 12 419 426 10.1016/0264-410X(94)90118-X 8023550
69. Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine. SI Tamura H Asanuma Y Ito Y Hirabayashi Y Suzuki T Nagamine C Aizawa T Kurata A Oya, Eur J Immunol 1992 22 477 481 10.1002/eji.1830220228 1537382
70. Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. BZ Wang FS Quan SM Kang J Bozja I Skountzou RW Compans, J Virol 2008 82 11813 11823 10.1128/JVI.01076-08 18786995